How Does Cannabis Reduce Neuropsychiatric SymptomsĀ inĀ Dementia?Ā
As interest in medical cannabis expands, one question often asked is whether cannabinoids can help reduce neuropsychiatric symptoms such as agitation, anxiety, and sleep disturbance in people with dementia. Although some small studies suggest mild improvements, the biological mechanisms remain uncertain, and clinical evidence is limited.
According toĀ NHSĀ andĀ NICEĀ guidance, cannabis-based medical products areĀ not recommendedĀ for dementia symptoms because evidence is weak, inconsistent, and short-term (NHS Guidance;Ā NICE NG97;Ā NICE NG144).Ā
What Are Neuropsychiatric Symptoms?
Neuropsychiatric symptoms in dementia, also known as behavioural and psychological symptoms of dementia (BPSD), include agitation, irritability, aggression, depression, anxiety, delusions, and sleep disruption. These symptoms are distressing for patients and caregivers and often require complex management.
Current first-line treatments include non-drug behavioural approaches, environmental adjustments, and when needed, carefully supervised medications such as antidepressants or antipsychotics. Researchers have explored whether cannabinoids could offer an alternative.
How Cannabinoids Might Work in the Brain
Cannabinoids like THC (tetrahydrocannabinol) and CBD (cannabidiol) act on the bodyās endocannabinoid system (ECS), a network of receptors that help regulate mood, sleep, pain, and memory. In theory, by modulating these receptors, especially CB1 and CB2, cannabinoids could influence the emotional and behavioural pathways that become dysregulated in dementia.
Some laboratory studies suggest that cannabinoids may reduce inflammation, oxidative stress, and excitotoxicity, all processes that can worsen neuropsychiatric symptoms. However, translating these findings into meaningful clinical benefits remains a major challenge.
A 2024 commentary from the Johns Hopkins Center for Psychedelic and Consciousness Research concluded that while the ECS plays a role in emotional regulation, evidence for cannabinoids improving neuropsychiatric symptoms in dementia is preliminary and should be limited to controlled clinical trials (Frontiers in Aging Neuroscience, 2024).
What Clinical Studies Have Found
2023 Randomised Controlled Trial
A 2023 double-blind crossover trial (n=21, mean age 85) assessed cannabinoids for agitation and anxiety in dementia. Results showed small improvements in agitation but no meaningful effects on anxiety, sleep, or overall quality of life compared with placebo (PubMed Study).
2024 Swiss Feasibility Study
A 2024 Swiss feasibility study of oral THC/CBD oil found that treatment was well tolerated and may have reduced pain and restlessness in severe dementia, but the results were not statistically significant (Swiss Study). Researchers concluded that cannabinoids were safe for short-term use, but that efficacy remains unclear.
2024ā2025 Systematic Reviews
Systematic reviews published in 2024 and 2025, including a meta-analysis of 12 clinical studies, confirmed that cannabinoids may have modest calming or sedative effects, but not enough to change clinical practice. Improvements in agitation were inconsistent, and no review demonstrated significant benefit for mood, sleep, or cognition (Meta-Analysis, 2024).
Limitations And Safety Concerns
While cannabinoids are generally well tolerated, studies report side effects such as drowsiness, dizziness, confusion, and increased fall risk in older adults. These effects are particularly concerning in dementia, where balance and alertness are already compromised.
The World Health Organization (WHO) warns that data on long-term cognitive and neuropsychiatric safety in dementia are inadequate. It concludes that cannabinoids should not be used for behavioural or psychological symptoms outside research settings (WHO: Cannabis and Cannabinoids).
What The Guidelines Say
Both NICE and NHS guidance reaffirm that cannabinoids are not licensed for dementia symptoms. The 2023 NICE surveillance review found no new evidence to support updating clinical guidelines or expanding use beyond approved conditions such as severe epilepsy, chemotherapy-induced nausea, and multiple sclerosis spasticity (NICE 2023 Surveillance Review).
The Clinical Bottom Line
- Cannabinoids act on the endocannabinoid system, which regulates mood andĀ behaviour.Ā
- Laboratory research suggests potential neuroprotective and calming effects, but clinical results are inconsistent.Ā
- Small studies show modest reductions in agitation, but no improvements in cognition, sleep, or quality of life.Ā
- NICE, NHS, WHO, and Johns Hopkins researchers agree that evidenceĀ remainsĀ preliminary.Ā
- Cannabis should only be used for dementia-related symptoms inĀ controlled clinical research, not routine care.Ā
Educational Context: AlleviMed
Educational organisations such as AlleviMed help patients understand how medical cannabis eligibility is assessed in the UK. They clarify that cannabis-based medicines are only prescribed for licensed conditions under strict supervision. Dementia and neuropsychiatric symptoms are not approved indications and remain research-only areas.
Takeaway
Cannabis may act on brain pathways that influence mood and behaviour, but current research shows no consistent clinical benefit for reducing neuropsychiatric symptoms in dementia. According to NHS, NICE, WHO, and Johns Hopkins experts, cannabinoids should only be studied further in regulated clinical trials, not used as standard treatment.
